Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study

BackgroundCirrhotic refractory ascites (RA) patients have few alternatives for treatment. Empagliflozin is now known to have natriuretic and neurohormonal modulatory effects. This research investigated the safety and efficacy of empagliflozin in the management of RA when added to the standard of car...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Liver Journal 2024-10, Vol.14 (1), p.76-10
Main Authors: Bakosh, Mohamed Fathy, Ghazy, Ramy Mohamed, Ellakany, Walid Ismail, Kamal, Ahmed
Format: Article
Language:English
Subjects:
Ascites
Asymptomatic
Blood pressure
Creatinine
Diabetes
Diabetic ketoacidosis
Diuretics
Drug dosages
Empagliflozin
Glucose
Hypoglycemia
Hyponatremia
Kidneys
Liver cirrhosis
Muscle pain
Natriuretic agents
Patients
Sodium
Sodium-glucose transporter 2 inhibitors
Ultrasonic imaging
Urinary tract diseases
Urinary tract infections
Urine
Urogenital system
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundCirrhotic refractory ascites (RA) patients have few alternatives for treatment. Empagliflozin is now known to have natriuretic and neurohormonal modulatory effects. This research investigated the safety and efficacy of empagliflozin in the management of RA when added to the standard of care (SoC) compared to SoC alone.MethodsPatients were randomized to receive either a fixed dose of 10 mg of empagliflozin plus standard of care (SoC) or SoC alone. Patients were followed up for 3 months. The primary endpoint was achieving no need for large-volume paracentesis (LVP).ResultsForty-two patients were randomized equally, and intention-to-treat was performed. There was a statistically significant decrease in the need for LVP in the empagliflozin group compared to the SoC group (100% in the SoC vs. 42.9% in the empagliflozin group, p 
ISSN:2090-6218
2090-6226
DOI:10.1186/s43066-024-00383-y